OBESIAL: A Prospective Interventional Real-world Study of a Multidisciplinary Obesity Management Programme

What Was Tested

This registered not phased trial tested Semaglutide.

It had three arms (groups): G1a: Structured Obesity Care + Semaglutide (experimental), G1b : Structured care group / lifestyle intervention alone (active comparator) and G2: Non-structured care group (active comparator).

The registry classes the interventions as behavioral, drug and other.

More on the Plan

The primary comparison evaluates outcomes between participants receiving structured multidisciplinary care (G1, n=150) and those receiving non-structured usual care (G2, n=150).

The structured pathway includes coordinated medical follow-up, personalised nutritional intervention, adapted physical activity, therapeutic education, and multidisciplinary support.

Within the structured care group, eligible participants will undergo a nested randomised comparison between G1a (lifestyle intervention plus GLP-1 receptor agonist therapy) and G1b (lifestyle intervention alone) to assess the additional effect of GLP-1 receptor agonist treatment.

Secondary outcomes include changes in body composition, metabolic parameters, treatment response, adherence, and obesity-related outcomes.

Who Took Part

Enrollment: 300 planned participants were the target.

It was open to people of any sex aged from 18 years up to 65 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Adults aged 18-65 years. BMI ≥30 kg/m². Written informed consent obtained prior to enrolment.

The full record lists 3 inclusion and 13 exclusion criteria; among the exclusions: refusal to participate or inability to adhere to follow-up procedures; pregnancy at enrolment; recent acute cardiovascular event (\<60 days).

How the Study Was Run

It was run as a randomized, parallel-group and open-label study.

The participants were allocated by chance, so the Semaglutide group and the comparison group should start out alike.

The Semaglutide group and the comparison group ran side by side rather than switching.

Everyone knew when Semaglutide was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

It started in 2026-01-22 with completion listed for 2028-01-23.

It ran at 1 site in Algeria.

Its stated primary purpose is treatment.

What Was Measured

It also tracked 7 secondary outcomes, for example Baseline predictors of weight loss response to semaglutide at Month 18, Change in glycemic parameters from baseline to Month 18, Change in lipid parameters from baseline to Month 18 and Change in body composition from baseline to Month 18.

What This Means in Plain Language

Put simply, this is a not phased, randomized trial of Semaglutide in 300 people.

It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Semaglutide compound page, all human trials.